Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use LETAIRIS® safely and effectively. See full prescribing information for LETAIRIS. Letairis (ambrisentan) tablets, for oral use Initial U.S. Approval: 2007
Medication labelWhy this: Advisory · dailymed-prescription
Letairis is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in adult patients: To improve exercise ability and delay clinical worsening. In combination with tadalafil to reduce the risks of disease progression and hospitalization for worsening PAH, and to improve exercise ability [see Clinical Studies (14.2)]. Studies establishing effectiveness included predominantly patients with WHO Functional Class II–III symptoms and etiologies of idiopathic or heritable PAH (60%) or PAH associated with connective tissue diseases (34%).
- generic_name
- ambrisentan
- product_names
- AMBRISENTAN
- ndc
- 61958-0801, 61958-0801-2, 61958-0801-3, 61958-0801-1, 61958-0801-5, 61958-0801-4, 61958-0801-6, 61958-0802, 61958-0802-2, 61958-0802-3, 61958-0802-1, 61958-0802-5
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en